Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication.
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ epidemiology
Drug Therapy, Combination
/ methods
Elasticity Imaging Techniques
/ statistics & numerical data
Female
Follow-Up Studies
Hepacivirus
/ isolation & purification
Hepatitis C, Chronic
/ diagnosis
Humans
Incidence
Liver
/ diagnostic imaging
Liver Neoplasms
/ epidemiology
Male
Middle Aged
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Sustained Virologic Response
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 01 2022
27 01 2022
Historique:
received:
13
09
2021
accepted:
12
01
2022
entrez:
28
1
2022
pubmed:
29
1
2022
medline:
8
3
2022
Statut:
epublish
Résumé
Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age ≥ 71 years (hazard ratio [HR]: 3.402) and LSM ≥ 9.2 kPa (HR: 6.328); SVR24 factors were age ≥ 71 years (HR: 2.689) and LSM ≥ 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (≥ 9.2 kPa) and SVR24 LSM (≥ 8.4 kPa) and age (≥ 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up.
Identifiants
pubmed: 35087141
doi: 10.1038/s41598-022-05492-5
pii: 10.1038/s41598-022-05492-5
pmc: PMC8795443
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1449Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0210072h0001
Informations de copyright
© 2022. The Author(s).
Références
J Gastroenterol. 2005 Feb;40(2):148-56
pubmed: 15770398
Clin Gastroenterol Hepatol. 2006 Mar;4(3):369-80
pubmed: 16527702
Hepatology. 2005 Jan;41(1):48-54
pubmed: 15690481
J Hepatol. 2014 Jul;61(1):67-74
pubmed: 24613362
J Gastroenterol. 2014 Nov;49(11):1504-13
pubmed: 24317936
PLoS One. 2012;7(9):e44930
pubmed: 23049764
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Intern Med. 1999 Aug 3;131(3):174-81
pubmed: 10428733
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30381417
BMJ. 1995 Mar 11;310(6980):633
pubmed: 7703752
Clin Infect Dis. 2016 Sep 15;63(6):723-9
pubmed: 27282709
J Antimicrob Chemother. 2012 Nov;67(11):2766-72
pubmed: 22899800
J Hepatol. 2017 Mar;66(3):504-513
pubmed: 27818234
J Hepatol. 2016 Oct;65(4):769-775
pubmed: 27238753
Hepatology. 2016 Jul;64(1):130-7
pubmed: 26946190
Hepatology. 2013 Mar;57(3):964-73
pubmed: 22991257
J Gastroenterol Hepatol. 2005 May;20(5):752-8
pubmed: 15853990
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
PLoS One. 2018 Apr 19;13(4):e0195173
pubmed: 29672518
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Hepatol Res. 2018 Dec;48(13):1131-1139
pubmed: 30030872
J Hepatol. 2018 Nov;69(5):1088-1098
pubmed: 30138686
J Gastroenterol. 2017 Dec;52(12):1252-1257
pubmed: 28477171
Hepatology. 2013 Oct;58(4):1253-62
pubmed: 23564522
Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95
pubmed: 24321207
Hepatology. 2010 Aug;52(2):518-27
pubmed: 20683951
Hepatol Res. 2017 Sep;47(10):1021-1031
pubmed: 27859993
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Cancer. 2004 Oct 1;101(7):1616-22
pubmed: 15378504
J Gastroenterol Hepatol. 2015 Jul;30(7):1183-9
pubmed: 25678094
Clin Gastroenterol Hepatol. 2015 May;13(5):1017-24
pubmed: 25460552
J Hepatol. 2020 Mar;72(3):472-480
pubmed: 31629779
J Rural Med. 2019 May;14(1):78-86
pubmed: 31191770
Hepatol Res. 2019 Feb;49(2):136-146
pubmed: 30335208
J Gastroenterol Hepatol. 2018 Nov;33(11):1904-1911
pubmed: 29744922
Clin Infect Dis. 2021 Nov 2;73(9):e3349-e3354
pubmed: 33544129
Hepatol Res. 2019 May;49(5):570-578
pubmed: 30623521
Liver Int. 2016 Dec;36(12):1793-1799
pubmed: 27254286
Hepatol Res. 2019 Oct;49(10):1207-1217
pubmed: 31219667
World J Gastroenterol. 2007 Oct 21;13(39):5180-7
pubmed: 17876888
Hepatology. 2020 Dec;72(6):1924-1934
pubmed: 33022803
Hepatology. 2012 Dec;56(6):2125-33
pubmed: 22767302
Liver Int. 2012 Apr;32(4):612-21
pubmed: 22103765
J Med Virol. 2011 Jun;83(6):1016-22
pubmed: 21503914
PLoS One. 2015 Jun 12;10(6):e0129053
pubmed: 26070204
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
Int J Cancer. 2011 May 15;128(10):2344-52
pubmed: 20669224
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Sci Rep. 2019 Jul 12;9(1):10109
pubmed: 31300805
Aliment Pharmacol Ther. 2018 Jan;47(1):104-113
pubmed: 29035002
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2616-2618
pubmed: 30502507
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908